Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Radiology|June 24, 2009
US surveillance of regional lymph node recurrence after breast cancer surgeryHee Jung Moon, Min Jung Kim, Eun-Kyung Kim, et al.
Breast Cancer Research and Treatment|August 30, 2020
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinibJi-Yeon Kim, Kyunghee Park, Seock-Ah Im, et al.
International Journal of Cancer|November 28, 2018
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A reviewKamal Pandey, Hee-Jung An, Seung Ki Kim, et al.
Breast Cancer Research and Treatment|March 1, 2017
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancerHyung Soon Park, Joohyuk Sohn, Seung Il Kim, et al.
Iscience|August 19, 2024
Reversion of pathogenic <i>BRCA1</i> L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancerSe-Young Jo, Jeong Dong Lee, Jeongsoo Won, et al.
Plos One|February 12, 2016
Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast CancerSeho Park, Jung Hyun Yoon, Joohyuk Sohn, et al.
Cancer Medicine|July 15, 2022
Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHPJung Hwan Ji, Soong June Bae, Seul-Gi Kim, et al.
NPJ Breast Cancer|June 23, 2021
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroupsStephen Johnston, Joyce O'Shaughnessy, Miguel Martin, et al.
Cancer Research and Treatment|September 22, 2018
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/CyclophosphamideGun Min Kim, Joo Hoon Kim, Ji Heung Kim, et al.
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Radiology|June 24, 2009
US surveillance of regional lymph node recurrence after breast cancer surgeryHee Jung Moon, Min Jung Kim, Eun-Kyung Kim, et al.
Breast Cancer Research and Treatment|August 30, 2020
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinibJi-Yeon Kim, Kyunghee Park, Seock-Ah Im, et al.
International Journal of Cancer|November 28, 2018
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A reviewKamal Pandey, Hee-Jung An, Seung Ki Kim, et al.
Breast Cancer Research and Treatment|March 1, 2017
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancerHyung Soon Park, Joohyuk Sohn, Seung Il Kim, et al.
Iscience|August 19, 2024
Reversion of pathogenic <i>BRCA1</i> L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancerSe-Young Jo, Jeong Dong Lee, Jeongsoo Won, et al.
Plos One|February 12, 2016
Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast CancerSeho Park, Jung Hyun Yoon, Joohyuk Sohn, et al.
Cancer Medicine|July 15, 2022
Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHPJung Hwan Ji, Soong June Bae, Seul-Gi Kim, et al.
NPJ Breast Cancer|June 23, 2021
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroupsStephen Johnston, Joyce O'Shaughnessy, Miguel Martin, et al.
Cancer Research and Treatment|September 22, 2018
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/CyclophosphamideGun Min Kim, Joo Hoon Kim, Ji Heung Kim, et al.
Pageof 13